Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aurinia Pharm Ord 14315 - 118 AVENUE SUITE 140 EDMONTON A0 T5L 4S6 CAN

www.auriniapharma.com P: 250-744-2487 F: 604-369-4115

Description:

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Key Statistics

Overview:

Market Capitalization, $K 727,429
Enterprise Value, $K 678,549
Shares Outstanding, K 144,618
Annual Sales, $ 175,510 K
Annual Net Income, $ -78,020 K
Last Quarter Sales, $ 45,100 K
Last Quarter Net Income, $ -26,880 K
EBIT, $ -83,310 K
EBITDA, $ -71,660 K
60-Month Beta 1.36
% of Insider Shareholders 4.30%
% of Institutional Shareholders 36.83%
Float, K 138,399
% Float 95.70%
Short Volume Ratio 0.53

Growth:

1-Year Return -56.01%
3-Year Return -63.30%
5-Year Return -21.45%
5-Year Revenue Growth 38,054.35%
5-Year Earnings Growth 28.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.19 on 02/15/24
Latest Earnings Date 05/02/24 [BMO]
Earnings Per Share ttm -0.54
EPS Growth vs. Prev Qtr -111.11%
EPS Growth vs. Prev Year -5.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 11/08/13

AUPH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -20.10%
Return-on-Assets % -14.83%
Profit Margin % -44.45%
Debt/Equity 0.00
Price/Sales 4.19
Price/Cash Flow N/A
Price/Book 1.92
Book Value/Share 2.63
Interest Coverage -26.87
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar